$EHC

COLTHARP DOUGLAS E sold $2.4M of EHC

COLTHARP DOUGLAS E (EVP & Chief Financial Officer) sold 18,869 shares of Encompass Health Corp (EHC) at $125.38 ($2.37M total) on 2026-08-10.

Original reporting
SEC EDGAR · COLTHARP DOUGLAS E
Published Aug 11, 2026, 6:47 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 11, 2026, 6:49 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$EHC
Neutral
medium confidence
Mentioned
$EHC
Relevance
6/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$EHCNeutralLow
01

Why it matters

Insider selling can slightly pressure sentiment, but without accompanying operational or financial updates, it is unlikely to drive a sustained repricing.

02

Market read

Traders may note the insider sale for sentiment monitoring, but there is no new guidance, contract, or regulatory development.

03

What to watch

The article does not state whether the sale was part of a 10b5-1 plan (it says no), but it also provides no context on motivations or future trading intentions.

Relevance 6/10Novelty 3/10Timing: today’s SEC Form 4 filing

Background

The article is an SEC Form 4 insider transaction disclosure for Encompass Health Corp.

Company-level read

Ticker impact

$EHCNeutralMedium confidence
Context

Encompass Health CFO Coltharp Douglas sold 18,869 shares in an open-market transaction worth about $2.37M, per Form 4 filed today.

Expected impact

Likely limited, short-lived impact unless paired with other negative news.

Evidence & confidence

The filing is a routine Form 4 open-market sale with no 10b5-1 plan stated; insider selling can be interpreted both ways, and the article provides no earnings, guidance, or operational catalyst.

Market effects

Minimal, as the disclosure is company-specific insider selling without sector-wide signal.

None indicated.

None indicated.

Counterpoint

The sale may be unrelated to fundamentals (taxes, diversification, planned liquidity needs), so it should not be over-weighted.

Key entities

  • Encompass Health Corp

    Subject of the Form 4 insider transaction disclosure.

  • COLTHARP DOUGLAS E

    EVP and Chief Financial Officer who sold shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$EHCMed

Encompass Health Named Top SMidCap Pick by TD Cowen

TD Cowen analyst Ryan Langston reiterated Encompass Health (EHC) as a top small- and mid-cap pick after its strong Q2 FY2026 results. Adjusted EBITDA was $348M (+3% vs consensus), revenue $1.597B (+10%), and EPS $1.55. Same-store volume rose 2.8%. EHC raised FY2026 adjusted EBITDA guidance by $15M and authorized a $1B share repurchase.

$EHCMedAI 8/10

Encompass Health Lifts 2026 Outlook Amid Strong Q2

Encompass Health (EHC) reported Q2 results and raised 2026 guidance. Q2 revenue rose 9.6% to support adjusted EBITDA of $348 million (+9.2%) and adjusted EPS up 10.7%. Full-year 2026 net operating revenue is guided to $6.41B-$6.49B, adjusted EBITDA $1.365B-$1.395B, and adjusted EPS $6.02-$6.25.

$EHCMed

Encompass Health Q2 Earnings Call Highlights

Encompass Health (NYSE:EHC) discussed Q2 updates on an earnings call. It expects Medicare pricing impact of about 2.3% in Q4 and 2026 salary/wage growth of 3.5% to 4.0%. It cut the 2026 net provider-tax benefit to about $10M from ~$21M. The company opened new beds, raised its dividend to $0.21, repurchased shares, and issued $500M notes, with net leverage at 1.9x.

$EHCMed

Encompass Health (EHC) Is Up 12.7% After Raising 2026 Guidance And Completing Major Buyback Program – Has The Bull Case Changed?

Encompass Health (EHC) reported Q2 2026 net operating revenue of $1,597.4 million and net income of $153.9 million, with higher EPS year over year. The company raised full-year 2026 revenue guidance and completed a major share repurchase program, retiring nearly one-tenth of shares, and increased shareholder returns. The article also cites higher debt after 2034 notes.